Gilead Sciences (BSP:GILD34) Institutional Ownership : 0.00% (As of May. 01, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Gilead Sciences Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Gilead Sciences's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Gilead Sciences's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Gilead Sciences's Float Percentage Of Total Shares Outstanding is 0.00%.

Gilead Sciences Institutional Ownership Historical Data

The historical data trend for Gilead Sciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Institutional Ownership Chart

Gilead Sciences Historical Data

The historical data trend for Gilead Sciences can be seen below:

	2019-03-31	2019-04-30	2019-05-31	2019-06-30	2019-07-31	2020-10-31	2020-11-30	2021-10-31	2021-11-30	2022-01-31
Institutional Ownership	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01

Gilead Sciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Gilead Sciences (BSP:GILD34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BSP:GILD34) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Gilead Sciences (BSP:GILD34) Headlines

No Headlines